Thermo Fisher Announces PeproTech Acquisition

Column, February 2022, Volume 18, Issue 2
Pages: 8

Thermo Fisher Scientific Inc. (Waltham, Massachusetts, USA) has completed the acquisition of PeproTech, Inc. (New Jersey, USA), a developer and manufacturer of recombinant proteins, for a total of approximately $1.85 billion.

PeproTech is a privately held provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models.

“PeproTech will be an excellent strategic fit within our biosciences business and will allow us to even better serve our pharma and biotech customers by adding new capabilities to our existing offering,” said Marc N. Casper, Chairman, President and Chief Executive Officer of Thermo Fisher Scientific.

PeproTech will become part of the biosciences business within Thermo Fisher and will be integrated into the Life Sciences Solutions Segment.

For more information, please visit: https://corporate.thermofisher.com